MODERN POTENTIALS FOR CORRECTION OF ACTIVITY OF NEUROHUMORAL SYSTEMS IN PATIENTS WITH MYOCARDIAL INFARCTION


Cite item

Full Text

Abstract

This article is dedicated to modern methods of pharmacological correction of neurohumoral systems activity in various stages of myocardial infarction. It is emphasized that following of current guidelines is not always effective in prophylaxis of the left ventricle remodeling. Possibilities of new drug groups usage for this aim are discussing.

References

  1. Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST ЭКГ. Национальные рекомендации. Кардиоваскулярная терапия и профилактика 2007. №6(8).
  2. Antman EM, Hand M, Armstrong PW, et al. ACС/AHA 2007 Focused Update of the 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Circulation 2008;V.117:296-329.
  3. Management of Acute Myocardial Infarction in patients presenting with ST-segment elevation ESC Clinical Practice Guidelines. Eur Heart J 2008;29:2909-45.
  4. Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327(10):678-84.
  5. Ambrosioni E, Borghi C, Magnani B, et al. For the Survival of Myocardial infarction Long-Term Evaluation Study Investigators (SMILE Study). The effect of angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-85.
  6. Gruppo Italiano per lo studio della Soprawivenza nell'infarto miocardico GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343(8906):1115-22.
  7. Перепеч Н.Б., Михайлова И.Е., Лясникова Е.А. Применение лизиноприла с первых суток инфаркта миокарда у больных, получивших системную тромболитическую терапию // Гедеон Рихтер в СНГ 2001. № 4. C. 17-19.
  8. Borghi C, Marino P, Zardini P,et al. Post acute myocardial infarction: the Fosinopril in Acute Myocardial Infarction Study (FAMIS). Am J Hypertens 1997;10(10Pt2):247-54.
  9. ISIS-4 (Fourth International Study of Infarct Survival Collaborative Group): A randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1994;345(8951):669-85.
  10. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial (SAVE). N Engl J Med 1992;327(10):669-77.
  11. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence heart failure. Lancet 1993;342(8875):821-27.
  12. Астахова З.Т., Кайтова З.Э., Мрикзев В.К., Салбиева Г.У. Клиническая эффективность ингибитора АПФ рамиприла при левожелудочковой недостаточности на фоне инфаркта миокарда // Российский Кардиологический Журнал 1999. № 4. C. 9.
  13. Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006;166(6):659-66.
  14. Foy SG, et al. Comparison of enalapril versus captopril on left ventricular function and survival three months after acute myocardial infarction (the "PRACTICAL" study). Am J Cardiol 1994;73(16):1180-86.
  15. Сидоренкова Н.Б., Пляшешников М.А. Сравнительная эффективность эналаприла и фосиноприла при остром инфаркте миокарда // Российский Кардиологический Журнал 1999. № 4 (приложение). C. 150.
  16. Sun YP, Zhu BQ, Browne AE, et al. Comparative effects of ACE inhibitors and angiotensin receptor blocker on atherosclerosis and vascular function. J Cardiovasc Pharmacol Ther 2001;6:175-81.
  17. Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2008;29:2388-442.
  18. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
  19. Pitt B, Poole-Wilson P, Segal R, et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: Losartan Heart Failure Survival Study - ELITE II. J Card Fail 1999;5:146-54.
  20. McMurray J, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362(9386):767-71.
  21. Диагностика и лечение хронической сердечной недостаточности. Национальные рекомендации (третий пересмотр) // Журнал Сердечная недостаточность 2010. № 1(57). Т.1.
  22. Чукаева И.И., Ощепкова М.В., Богова О.Т. и др. Влияние терапии антагонистом рецепторов ангиотензина II лозартаном и ингибитором ангиотензин-превращающего фермента эналаприлом на постинфарктное ремоделирование левого желудочка // Российский кардиологический журнал 2001. № 5. C. 41-45.
  23. Коц Я.И., Лебедянцев Л.В., Сайфутдинов Р.И., Бобылев В.В. Использование блокаторов рецепторов ангиотензина II для лечения левожелудочковой недостаточности в остром периоде инфаркта миокарда // Кардиология 2001. № 1. C. 30-33.
  24. Пархоменко А.Н., Иркин О.И., Брыль Ж.В. и др. Опыт применения ингибитора ангиотензинпревращающего фермента капотена и блокатора рецепторов ангиотензина ирбесартана в ранние сроки острого инфаркта миокарда // Украинский кардиологический журнал 2000. № 3. C. 5-8.
  25. Амосова Е.Н., Запорожец О.Б., Казаков В.Е. и др. Влияние ингибитора ангиотензинпревращающего фермента эналаприла и блокатора рецепторов ангиотензина лозартана на раннее ремоделирование левого желудочка у больных с острым инфарктом миокарда и его клиническое течение // Укр. мед. часопис 1999. № 4. C. 91-96.
  26. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360(9335):752-60.
  27. Pfeffer MA, McMurray J, et al. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. N Eng J Med 2003;349:1893-906.
  28. Pitt B, Williams G, Remme W, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction: Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001;15:79-87.
  29. Adamopoulos C, Ahmed Ali, Fay R, et al. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS. Eur J Heart Fail 2009;11(11):1099-105.
  30. Fraccarollo D, Galuppo P, Schmidt I, et al. Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction. Cardiovasc Res 2005;67(1):97-105.
  31. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003;107(20):2559-65.
  32. Арутюнов Г.П., Розанов А.В., Вершинин А.А. Влияние полной блокады ренин-ангиотензин-альдостероновой системы антагонистом ангиотензина II и антагонистом альдостерона на течение сердечной недостаточности у больных с острым инфарктом миокарда после успешного системного тромболизиса // Журнал Сердечная недостаточность 2000. №1(1).
  33. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006;368(9545):1449-56.
  34. McMurray J, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17-24.
  35. Solomon S, et al. Effect of the Direct Renin Inhibitor Aliskiren on Left Ventricular Remodelling Following Myocardial Infarction with Left Ventricular Dysfunction: ASPIRE. Late Breaker presentation at American College of Cardiology 59th Annual Scientific Sessions 2010.
  36. Scirica BM, Morrow DA, Bode C, et al. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. Eur Heart J 2010;31(16):1993-2005.
  37. Rossi GP. Dual ACE and NEP inhibitors: a review of the pharmacological properties of MDL 100, 240. Cardiovasc Drug Review 2003;21:51-66.
  38. Packer M, Califf RM, Konstam MA, et al. Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure. The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106:920-26.
  39. Niccoli G, Lanza GA, Shaw S, et al. Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous mediator after successful percutaneous myocardial revascularization. Eur Heart J 2006;27(15):1793-98.
  40. Chen HH, Martin FL, Gibbons RJ, et al. Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study. Heart 2009;95:1315-19.
  41. Hillock RJ, Frampton CM, Richards AM et al. B-type natriuretic peptide infusions in acute myocardial infarction. Heart 2008;94:617-22.
  42. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007;370:1483-93.
  43. Konstam MA, et al. Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome Trial. JAMA 2007;297:1319-31.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies